Jeanne Fabre is an associate in the Paris office of Latham & Watkins and a member of the firm's Healthcare & Life Sciences Practice. She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, market access, promotion and advertising, post-market obligations, contracts, and general compliance matters.

Ms. Fabre has experience working in pharmaceutical companies. Since her Master II, she has worked more than three years for several companies both for local affiliates and parent company. She was part-time seconded for 18 months to a pharmaceutical company specializing in rare diseases, and a further three months to another pharmaceutical company. She worked on a wide range of regulatory topics (such as observational, ATU and post-ATU studies, service providers, consultancy, pay for performance agreements, and pricing topics).

Ms. Fabre's experience includes advising:

  • ArchiMed Portfolio Company, Natus Medical Incorporated, in its acquisition of Micromed Holding SAS
  • BC Partners, a leading international investment firm, on its exclusive negotiations to acquire a majority stake in Havea, the French leader in natural healthcare serving the European market
  • Astorg on its binding agreement to acquire CordenPharma, a leading pharmaceutical contract development and manufacturing organization, from International Chemical Investors Group (ICIG), a privately owned industrial group
  • A leading European pharmaceutical industry association on various strategic legal and policy analyses of the EU framework regulating innovation in pharmaceutical product development, including in-depth assessments of accelerated approval pathways, drug repurposing, eERA and complex and virtual clinical trials, the SPC manufacturing waiver, and a variety of other cutting-edge issues that have inspired the EMA Regulatory Science Strategy and the European Commission’s Pharmaceutical Strategy*
  • Successfully defending a pharmaceutical company in commercial litigations regarding medicines advertising proceedings in France*
  • A broad range of life sciences actors on health emergency procedures and the regulatory and legal risks and liabilities related to the rapid development and availability of COVID-19 diagnostic tests, including the emergency use of clinical and diagnostic labs, the self-assembly of diagnostic kits by employers, and the qualification and validity of different types of testing (including self-tests)*
  • A leading global online retailer and e-commerce platform on numerous legal and enforcement risk assessments related to the online sale and advertising of an extensive variety of regulated products in key EU member states, including the online sale of medicinal products (and related online pharmacy establishment requirements), diagnostic tests, medical devices, cosmetic products, food and beverages as well as other regulated products*
  • A broad range of companies active in the life sciences sector on French regulation related to anti-gift and transparency (“sunshine act”) obligations*
  • A number of well-known cosmetic and food and beverage companies on complex product qualification and borderline questions related to innovative products and associated cosmetic or health claims*
  • Various investment funds and pharmaceutical companies on the legal and regulatory framework and risk assessment of transactions related to medicines/medical devices and life sciences companies acquisition*

*Matter handled prior to joining Latham

Bar Qualification

  • Avocat (Paris)


  • Master II in Health Law, University of Paris V (Descartes), 2015
    cum laude - salutatorian
  • Master I in Business Law, University of Paris XII, 2014
    magna cum laude
  • Bachelor of Law in Private Law, Université de Poitiers, 2013
    cum laude

Languages Spoken

  • English